Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic‐Associated Fatty Liver Disease
Evidence-Based Complementary and Alternative Medicine · 2023-01 · 2023 (1)
DOI: 10.1155/2023/8840427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Evidence-Based Complementary and Alternative Medicine, online erschienen am 09.11.2023. Verfasst von Edilson Rodrigues Albuquerque und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Preclinical Research of Natural Products, Post Graduate Program in Animal Science with Emphasis on Bioactive Products, Universidade Par…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Araucária.
Abstract (Originalsprache)
Metabolic‐associated fatty liver disease (MAFLD) is a complex condition characterized by steatosis and metabolic disturbances. Risk factors such as diabetes, cigarette smoking, and dyslipidaemia contribute to its development and progression. Effective and safe therapies for MAFLD are urgently needed. Pereskia grandifolia has shown potential as an alternative treatment, but its effectiveness against liver disease remains unexplored. This research aims to determine the hepatoprotective properties of P. grandifolia using a model of MAFLD. The study was carried out through various phases to assess the safety and efficacy of the ethanol‐soluble fraction of P. grandifolia . Initially, an in vitro assay was performed to assess cell viability. This was followed by an acute toxicity test conducted in rats to determine the safety profile of the extract. Subsequently, the anti‐inflammatory properties of P. grandifolia were examined in macrophages. For the MAFLD study, diabetic Wistar rats were made diabetic and exposed to a high fat diet and cigarette smoke, for 4 weeks. During the last 2 weeks, the rats were orally given either the vehicle (negative control group; C‐), P. grandifolia (30, 100, and 300 mg/kg), or insulin in addition to simvastatin. A basal group of rats not exposed to these risk factors was also assessed. Blood samples were collected to measure cholesterol, triglycerides, glucose, ALT, and AST levels. Liver was assessed for lipid and oxidative markers, and liver histopathology was examined. P. grandifolia showed no signs of toxicity. It demonstrated anti‐inflammatory effects by inhibiting phagocytosis and macrophage spreading. The MAFLD model induced liver abnormalities, including increased AST, ALT, disrupted lipid profile, oxidative stress, and significant hepatic damage. However, P. grandifolia effectively reversed these changes, highlighting its potential as a therapeutic agent. These findings emphasize the significance of P. grandifolia in mitigating hepatic consequences associated with various risk factors.
Autor:innen und Institutionen
- Laboratory of Preclinical Research of Natural Products, Post Graduate Program in Animal Science with Emphasis on Bioactive Products, Universidade Paranaense, Umuarama, Brazil.
- Laboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil.
- School of Dentistry, São Paulo State University, Araçatuba, Brazil.
- Department of Genetic, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
- Laboratory of Preclinical Research of Natural Products, Post Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, Brazil.
- Department of Biotechnology, São Paulo State University, Assis, São Paulo, Brazil.
ORCID-Profile: Edilson Rodrigues Albuquerque, Gustavo Ratti da Silva, Fernanda de Abreu Braga, Ester Pelegrini Silva, Karina Sposito Negrini, Julia Amanda Rodrigues Fracasso, Lucas Pires Guarnier, Ezilda Jacomassi, João Tadeu Ribeiro-Paes, Roberto da Silva Gomes, Arquimedes Gasparotto Junior, Francislaine Aparecida Dos Reis Lívero
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Araucária
Zitieren
APA
Rodrigues Albuquerque, E., Ratti da Silva, G., de Abreu Braga, F., Pelegrini Silva, E., Sposito Negrini, K., Rodrigues Fracasso, J. A., Pires Guarnier, L., Jacomassi, E., Ribeiro-Paes, J. T., da Silva Gomes, R., Gasparotto Junior, A., & Lívero, F. A. D. R. (2023). Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic‐Associated Fatty Liver Disease. Evidence-Based Complementary and Alternative Medicine, 2023(1). https://doi.org/10.1155/2023/8840427
Vancouver
Rodrigues Albuquerque E, Ratti da Silva G, de Abreu Braga F, Pelegrini Silva E, Sposito Negrini K, Rodrigues Fracasso JA, et al. Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic‐Associated Fatty Liver Disease. Evidence-Based Complementary and Alternative Medicine. 2023;2023(1). doi:10.1155/2023/8840427
BibTeX
@article{RodriguesAlbuquerque2023,
author = {Rodrigues Albuquerque, Edilson and Ratti da Silva, Gustavo and de Abreu Braga, Fernanda and Pelegrini Silva, Ester and Sposito Negrini, Karina and Rodrigues Fracasso, Julia Amanda and Pires Guarnier, Lucas and Jacomassi, Ezilda and Ribeiro-Paes, João Tadeu and da Silva Gomes, Roberto and Gasparotto Junior, Arquimedes and Lívero, Francislaine Aparecida Dos Reis},
title = {Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic‐Associated Fatty Liver Disease},
journal = {Evidence-Based Complementary and Alternative Medicine},
year = {2023},
volume = {2023},
number = {1},
doi = {10.1155/2023/8840427}
}
EUVIMED